TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Pieris Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
What was Pieris Pharmaceuticals’s price range in the past 12 months?
Pieris Pharmaceuticals lowest stock price was $1.70 and its highest was $6.06 in the past 12 months.
What is Pieris Pharmaceuticals’s market cap?
Pieris Pharmaceuticals’s market cap is $390.26M.
What is Pieris Pharmaceuticals’s price target?
The average price target for Pieris Pharmaceuticals is $9.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 53.85% Increase from the current price of $5.85.
What do analysts say about Pieris Pharmaceuticals?
Pieris Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
When is Pieris Pharmaceuticals’s upcoming earnings report date?
Pieris Pharmaceuticals’s upcoming earnings report date is Nov 10, 2021 which is in 2 months.
How were Pieris Pharmaceuticals’s earnings last quarter?
Pieris Pharmaceuticals released its earnings results on Aug 04, 2021. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.03.
Is Pieris Pharmaceuticals overvalued?
According to Wall Street analysts Pieris Pharmaceuticals’s price is currently Undervalued.
Does Pieris Pharmaceuticals pay dividends?
Pieris Pharmaceuticals does not currently pay dividends.
What is Pieris Pharmaceuticals’s EPS estimate?
Pieris Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pieris Pharmaceuticals have?
Pieris Pharmaceuticals has 66,710,000 shares outstanding.
What happened to Pieris Pharmaceuticals’s price movement after its last earnings report?
Pieris Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went up 3.297%.
Which hedge fund is a major shareholder of Pieris Pharmaceuticals?
Among the largest hedge funds holding Pieris Pharmaceuticals’s share is Platinum Investment Management. It holds Pieris Pharmaceuticals’s shares valued at 4M.